Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup.

[1]  J. Freeman.  Seizures, EEG events, and the ketogenic diet , 2009, Epilepsia.

[2]  K. Kitchin,et al.  Measurement of oxidative stress parameters using liquid chromatography-tandem mass spectroscopy (LC-MS/MS). , 2008, Toxicology and applied pharmacology.

[3]  Yan Ling Zhang,et al.  HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. , 2007, Clinical chemistry.

[4]  P. Taylor.  Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. , 2005, Clinical biochemistry.

[5]  P. Montuschi,et al.  Isoprostanes: markers and mediators of oxidative stress , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  B. Halliwell,et al.  Rapid preparation of human urine and plasma samples for analysis of F2-isoprostanes by gas chromatography-mass spectrometry. , 2004, Biochemical and biophysical research communications.

[7]  P. Montuschi,et al.  Validation of 8-isoprostane and prostaglandin E2 measurements in exhaled breath condensate , 2003, Inflammation Research.

[8]  L. Wahlund,et al.  Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  M. Comporti,et al.  Ion trap tandem mass spectrometric determination of F2-isoprostanes. , 2003, Journal of mass spectrometry : JMS.

[10]  J. Hohlfeld,et al.  Divergence in urinary 8-iso-PGF2α (iPF2α-III, 15-F2t-IsoP) levels from gas chromatography–tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF2α: Possible methodological, mechanistic and clinical implicati , 2003 .

[11]  T. Annesley.  Ion suppression in mass spectrometry. , 2003, Clinical chemistry.

[12]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[13]  C. Heward,et al.  Quantification of 8-iso-prostaglandin-F2α and 2,3-dinor-8-iso-prostaglandin-F2α in human urine using liquid chromatography-tandem mass spectrometry , 2003 .

[14]  Walter A. Korfmacher,et al.  Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery. , 2003, Rapid communications in mass spectrometry : RCM.

[15]  J. Morrow,et al.  The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[16]  D. Kelley,et al.  Derivatization of F2-isoprostanes with 1-pyrenyldiazomethane and their subsequent determination by fluorescence high-performance liquid chromatography. , 2002, Analytical biochemistry.

[17]  T. Hishinuma,et al.  Simultaneous quantification of prostaglandins, isoprostane and thromboxane in cell-cultured medium using gas chromatography-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  D. Hirsch,et al.  Analysis of Monohydroxyeicosatetraenoic Acids and F2 -isoprostanes as Markers of Lipid Peroxidation in Rat Brain Mitochondria , 2002, Free radical research.

[19]  T. Montine,et al.  Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[20]  G. FitzGerald,et al.  The isoprostanes in biology and medicine , 2001, Trends in Endocrinology & Metabolism.

[21]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[22]  Timothy Olah,et al.  Mechanistic investigation of ionization suppression in electrospray ionization , 2000, Journal of the American Society for Mass Spectrometry.

[23]  N. Ohashi,et al.  Rapid and sensitive quantification of 8-isoprostaglandin F2α in human plasma and urine by liquid chromatography–electrospray ionization mass spectrometry , 2000 .

[24]  J. Satoh,et al.  Determination of urinary 8-epi-prostaglandin F(2alpha) using liquid chromatography-tandem mass spectrometry: increased excretion in diabetics. , 2000, Prostaglandins & other lipid mediators.

[25]  J. Blumberg,et al.  Streamlined F2-isoprostane analysis in plasma and urine with high-performance liquid chromatography and gas chromatography/mass spectroscopy. , 2000, Analytical biochemistry.

[26]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[27]  M. Reilly,et al.  Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. FitzGerald,et al.  Identification of Two Major F2 Isoprostanes, 8,12-Iso- and 5-epi-8,12-Iso-isoprostane F2α-VI, in Human Urine* , 1998, The Journal of Biological Chemistry.

[29]  G. FitzGerald,et al.  IPF2α-I: An index of lipid peroxidation in humans , 1998 .

[30]  B. Matuszewski,et al.  Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. , 1998, Analytical chemistry.

[31]  T. Montine,et al.  F2-isoprostanes in Alzheimer and other neurodegenerative diseases. , 2005, Antioxidants & redox signaling.

[32]  J. Morrow,et al.  Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. , 1999, Methods in enzymology.